Synbiotics

What Synbiotics does

Synbiotics Limited is an India-based fermentation pharmaceutical manufacturer incorporated in 1960 and headquartered in Vadodara, Gujarat. The company produces Active Pharmaceutical Ingredients (APIs) using fermentation processes, with its entire commercial portfolio centered on Amphotericin B — a critical antifungal agent. Synbiotics operates one of the few Amphotericin B manufacturing facilities in the world and the only one in India, manufacturing the API in three grade formats: oral grade (compliant with E.P., B.P., U.S.P., and J.P. pharmacopoeial standards), parenteral grade (E.P., B.P., U.S.P., I.P.), and lyophilized bulk for injection. The facility at Village Luna, Tal. Padra, Vadodara is positioned as a state-of-the-art manufacturing site designed to satisfy national and international regulatory requirements.

The company's core technology is fermentation-based API manufacturing, leveraging what it describes as "vast experience" in fermentation-derived products. Synbiotics has accumulated multi-jurisdictional regulatory approvals including WHO-GMP, USFDA (for oral and parenteral grades), Japanese PMDA (oral grade), EU-GMP (oral and parenteral grades), and a Written Confirmation for API export to Europe — credentials that gate access to most major regulated pharmaceutical markets. All commercial operations, including distribution and global sales, are executed through its closely associated group company Asence Pharma Private Limited, which functions as the company's commercial face. The go-to-market is a sales-led B2B model targeting pharmaceutical manufacturers that formulate Amphotericin B into finished drug products.

Beyond the core API business, Synbiotics holds a joint venture interest in CoSara Diagnostics Pvt. Ltd. (formed 2017 with Co-Diagnostics Inc-USA), which manufactures molecular diagnostic reagents and plans to establish diagnostic testing laboratories across Gujarat. CoSara is described as pursuing a DNA-based testing platform using computational mathematical models rather than traditional laboratory infrastructure. Ownership is closely held, with no disclosed external investment or public trading, and the company is part of a broader group that includes Asence Pharma, Telerad India, Teknoserv, Systronics India, Vovantis, and Sarabhai Chemicals.

Name

Synbiotics

Legal name

Synbiotics Limited

Website

https://synbiotics.in

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

51–100 employees

Short description

Synbiotics Limited is a Gujarat, India-based fermentation API manufacturer producing Amphotericin B in oral, parenteral, and lyophilized bulk grades for global pharmaceutical formulators, with WHO-GMP, USFDA, EU-GMP, and PMDA approvals.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (Pharmaceutical Manufacturing)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Pharmaceutical API manufacturing
• Fermentation-based APIs
• Amphotericin B production
• Active pharmaceutical ingredients
• Lyophilized injectable APIs

Headquarters

HQ city

Vadodara

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients Sales: Manufacturing and sale of fermentation-based Active Pharmaceutical Ingredients, specifically Amphotericin B in various grades (oral and parenteral). All commercial operations are handled by the group company Asence Pharma Private Limited.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Synbiotics Limited manufactures fermentation-based Active Pharmaceutical Ingredients (APIs), with its core portfolio centered on Amphotericin B supplied in oral grade, parenteral grade, and lyophilized bulk (for injection) forms. Production is carried out at a state-of-the-art facility in Village Luna near Vadodara, Gujarat, certified by WHO-GMP, USFDA, PMDA (Japan), and EU-GMP, and is sold to pharmaceutical manufacturers in India and international markets through its group company Asence Pharma Private Limited.

Product overview

Synbiotics Limited is a manufacturing company producing fermentation-based Active Pharmaceutical Ingredients (APIs). The company's core product portfolio centers on Amphotericin B in three formulations: oral grade (E.P/B.P./U.S.P./J.P.), parenteral grade (E.P/B.P./U.S.P./I.P.), and lyophilized bulk for injection. Synbiotics operates one of the few Amphotericin B manufacturing facilities in the world and the only such facility in India, located at Village Luna near Vadodara. Through a joint venture with Co-Diagnostics Inc-USA, the company also participates in the molecular diagnostics segment via CoSara Diagnostics, which produces diagnostic reagents and operates testing laboratories.

Differentiator

Problem solved

Functional benefit

Products and services

• Amphotericin B Oral Grade Fermentation-derived Active Pharmaceutical Ingredient of Amphotericin B in oral grade quality meeting E.P/B.P./U.S.P./J.P. pharmacopoeial standards. Supplied to pharmaceutical manufacturers for formulation of oral antifungal drug products.
• Amphotericin B Parenteral Grade Fermentation-derived Active Pharmaceutical Ingredient of Amphotericin B in parenteral grade quality meeting E.P/B.P./U.S.P./I.P. pharmacopoeial standards. Supplied to pharmaceutical manufacturers for formulation of injectable antifungal drug products.
• Amphotericin B for Injection (Lyophilized Bulk) Lyophilized bulk formulation of Amphotericin B for injection applications, produced at Synbiotics' state-of-the-art manufacturing facility for use by pharmaceutical manufacturers in injectable antifungal finished products.
• CoSara Diagnostics Molecular Diagnostic Reagents Molecular diagnostic reagents produced under the CoSara Diagnostics Pvt. Ltd. joint venture between Synbiotics Limited and Co-Diagnostics Inc-USA, intended for DNA-based testing platforms using computer-driven mathematical models rather than costly laboratory infrastructure. Targeted at diagnostic testing laboratories, including those planned across Gujarat State.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Asence Pharma Private LimitedcoreStrategic or Co-development PartnerAsence Pharma is the closely associated group company of Synbiotics Limited. All commercial operations including distribution and sales are undertaken by Asence Pharma Private Limited. Asence Pharma serves as the commercial face and handles all sales operations for Synbiotics' pharmaceutical products.
• Co-Diagnostics Inc (USA)coreStrategic or Co-development PartnerCoSara Diagnostics Pvt. Ltd. is a joint venture between Synbiotics and Co-Diagnostics Inc-USA. This is a state of the art molecular diagnostic reagents manufacturing company. The partnership aims to establish molecular diagnostic testing laboratories in Gujarat State and develop DNA-based testing platforms using mathematical models instead of costly laboratory infrastructure.

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Teva Pharmaceutical Industries: Global generic pharmaceutical major with extensive API manufacturing and a broad anti-infective portfolio. Comparable as a large-scale, multi-approved generic API competitor serving regulated markets.
• Sandoz: Novartis's generics and biosimilars division with a global API and finished-dose manufacturing footprint, including anti-infectives. Comparable as a broad incumbent in the regulated generic API space where Synbiotics competes.
• Alkem Laboratories: Indian pharmaceutical company with presence in antifungal formulations including Amphotericin B. Comparable as an India-based supplier in the same critical anti-infective therapeutic area.
• Cipla: Major Indian generic pharmaceutical manufacturer with global regulatory approvals and a portfolio that includes Amphotericin B products. Overlaps with Synbiotics in API/formulation manufacturing for anti-infectives at much larger scale.
• MSN Laboratories: Indian API and formulation manufacturer with USFDA- and EU-approved facilities serving global generics customers. Comparable as an India-based, multi-jurisdiction approved API competitor with similar B2B go-to-market.
• Aurobindo Pharma: Indian-headquartered global generic API and formulation manufacturer with strong USFDA-approved capabilities. Comparable as an India-based, multi-jurisdiction approved generic API supplier serving global pharmaceutical customers.
• Dr. Reddy's Laboratories: Indian pharmaceutical major with significant API and finished-dose generics operations across regulated markets, including anti-infectives. Comparable as a broad incumbent generic pharma company with India-based manufacturing.
• Viatris: Global generics and specialty manufacturer (formed from Mylan and Upjohn) with broad anti-infective API capabilities. Comparable as one of the world's largest multi-jurisdictional generic API producers.

Direct peers

• Xellia Pharmaceuticals: Denmark-based specialty pharmaceutical company focused on fermentation-derived anti-infective APIs including Amphotericin B. Closest direct comparable to Synbiotics as another fermentation-based, approved anti-infective API supplier serving global pharmaceutical manufacturers.
• Bharat Serums and Vaccines: Indian biopharmaceutical company with a strong portfolio of Amphotericin B formulations (including liposomal). Comparable as an Indian-headquartered player operating in the same therapeutic molecule space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/synbiotics-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synbiotics